Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2015 - 2026)

Insight Molecular Diagnostics has disclosed Total Current Liabilities across 12 years of filings, most recently posting $12.0 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $12.0 million, up 23.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 23.98% YoY), and the FY2025 annual result was $12.1 million, up 65.98% from the prior year.
• Total Current Liabilities came in at $12.0 million for Q1 2026 at Insight Molecular Diagnostics, down from $12.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $14.2 million in Q2 2022 to a low of $6.7 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $9.1 million (2024), against an average of $9.7 million.
• Across the five-year window, Total Current Liabilities sank 45.83% in 2023 and soared 65.98% in 2025, its largest moves.
• Insight Molecular Diagnostics' Total Current Liabilities stood at $12.1 million in 2022, then slumped by 40.57% to $7.2 million in 2023, then increased by 1.13% to $7.3 million in 2024, then jumped by 65.98% to $12.1 million in 2025, then slipped by 0.58% to $12.0 million in 2026.
• The last three Total Current Liabilities figures came in at $12.0 million (Q1 2026), $12.1 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.